Eduardo Ramacciotti
Overview
Explore the profile of Eduardo Ramacciotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
79
Citations
1060
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Neves S, Volpiani G, Paganotti A, Menegueti F, Boix R, Caffaro R, et al.
J Vasc Bras
. 2025 Feb;
24:e20240098.
PMID: 40012967
Anticholinergics have been shown to enhance quality of life and reduce sweat in patients with hyperhidrosis. However, it remains unclear whether topical application specifically exerts local or systemic effects. This...
2.
Ramacciotti E, Volpiani G, Britto K, Agati L, Ribeiro C, Aguiar V, et al.
NEJM Evid
. 2024 Aug;
3(9):EVIDoa2400021.
PMID: 39185955
Background: The combination of rivaroxaban plus aspirin compared with aspirin alone reduces the risk of major adverse cardiovascular and limb events for high-risk patients with peripheral artery disease. It is...
3.
Spyropoulos A, Ramacciotti E
Res Pract Thromb Haemost
. 2024 Jul;
8(4):102473.
PMID: 39040519
No abstract available.
4.
de Barros E Silva P, Macedo A, Bronhara B, Damiani L, Barbosa L, Lopes N, et al.
Circulation
. 2024 Jul;
150(1):82-85.
PMID: 38950107
No abstract available.
5.
de Barros E Silva P, Furtado R, de Alcantara Chaud M, Macedo A, Bronhara B, Damiani L, et al.
J Thromb Thrombolysis
. 2024 May;
57(6):1031-1039.
PMID: 38762708
Therapeutic anticoagulation showed inconsistent results in hospitalized patients with COVID-19 and selection of the best patients to use this strategy still a challenge balancing the risk of thrombotic and hemorrhagic...
6.
Siddiqui F, Hoppensteadt D, Jeske W, Ramacciotti E, Tafur A, Fareed J
Clin Appl Thromb Hemost
. 2024 Apr;
30:10760296241247558.
PMID: 38656136
Introduction: Andexanet alfa (AA) - zhzo, recombinant coagulation factor Xa, is an approved antidote for oral Xa inhibitors (apixaban and rivaroxaban). Unfractionated heparin (UFH) is commonly used for therapeutic, interventional,...
7.
Tavares I, Caffaro R, Portugal M, Ribeiro C, da Silva V, Krupa E, et al.
Clin Appl Thromb Hemost
. 2024 Apr;
30:10760296241238211.
PMID: 38566607
Venous thromboembolism (VTE), including deep venous thrombosis (DVT) and pulmonary embolism (PE), represents a substantial healthcare challenge. Provoked and unprovoked DVT cases carry distinct risks and treatment considerations. Recognizing the...
8.
Schulman S, Arnold D, Bradbury C, Broxmeyer L, Connors J, Falanga A, et al.
J Thromb Haemost
. 2024 Mar;
22(6):1779-1797.
PMID: 38503600
Based on emerging evidence from the COVID-19 pandemic, the International Society on Thrombosis and Haemostasis (ISTH) guidelines for antithrombotic treatment in COVID-19 were published in 2022. Since then, at least...
9.
Nicolaides A, Fareed J, Spyropoulos A, Kakkar R, Antignani P, Avgerinos E, et al.
Int Angiol
. 2024 Feb;
43(1):1-222.
PMID: 38421381
No abstract available.
10.
de Barros E Silva P, do Nascimento C, Pedrosa R, Arruda Nakazone M, do Nascimento M, de Araujo Melo L, et al.
Sci Rep
. 2024 Feb;
14(1):4222.
PMID: 38378735
There is limited contemporary prospective real-world evidence of patients with chronic arterial disease in Latin America. The Network to control atherothrombosis (NEAT) registry is a national prospective observational study of...